HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review
- PMID: 32047531
- PMCID: PMC7006188
- DOI: 10.1186/s13027-020-0278-x
HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review
Abstract
Background: Genital infection with certain types of Human papillomavirus (HPV) is a major cause of cervical cancer globally. For early detection of premalignant dysplasia, evidences are coming out on the usefulness of HPV E6/E7 mRNA test as a potential tool compared with cytology and HPV DNA testing. Taking into account shortage of compiled data on this field, the aim of this systematic review was to describe the latest diagnostic performance of HPV E6/E7 mRNA testing to detect high grade cervical lesions (CIN2+) where by histology was taken as a gold standard.
Methods: Articles published in English were systematically searched using key words from PubMed/Medline and SCOPUS. In addition, Google Scholar and the Google database were searched manually for grey literature. Two reviewers independently assessed study eligibility, risk of bias and extracted the data. We performed a descriptive presentation of the performance of E6/E7 mRNA test (in terms of sensitivity, specificity, negative and positive predictive values) for the detection of CIN2 + .
Results: Out of 231 applicable citations, we have included 29 articles that included a total of 23,576 study participants (age range, 15-84 years) who had different cervical pathologies. Among the participants who had cervical histology, the proportion of CIN2+ was between 10.6 and 90.6%. Using histology as a gold standard, 11 studies evaluated the PreTect HPV Proofer, 7 studies evaluated the APTIMA HPV assay (Gen-Probe) and 6 studies evaluated the Quantivirus® HPV assay. The diagnostic performance of these three most common mRNA testing tools to detect CIN2+ was; 1) PreTect Proofer; median sensitivity 83%, specificity 73%, PPV 70 and NPV 88.9%. 2) APTIMA assay; median sensitivity 91.4%, specificity 46.2%, PPV 34.3% and NPV 96.3%. 3) Quantivirus®: median sensitivity 86.1%, specificity 54.6%, PPV 54.3% and NPV was at 89.3%. Further, the area under the receiver operating characteristics (AU-ROC) curve varied between 63.8 and 90.9%.
Conclusions: The reported diagnostic accuracy implies that HPV mRNA based tests possess diagnostic relevance to detect CIN2+ and could potentially be considered in areas where there is no histology facility. Further studies including its cost should be considered.
Keywords: CIN2+; Diagnostic performance; HPV E6/E7 mRNA test.
© The Author(s). 2020.
Conflict of interest statement
Competing interestsThe authors declare that they have no competing interests.
Figures
Similar articles
-
Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review.Infect Agent Cancer. 2020 Nov 16;15(1):68. doi: 10.1186/s13027-020-00335-2. Infect Agent Cancer. 2020. PMID: 33292364 Free PMC article. Review.
-
Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.J Clin Microbiol. 2011 Nov;49(11):3794-9. doi: 10.1128/JCM.00549-11. Epub 2011 Sep 21. J Clin Microbiol. 2011. PMID: 21940473 Free PMC article.
-
High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.J Clin Microbiol. 2012 Jul;50(7):2390-6. doi: 10.1128/JCM.06587-11. Epub 2012 May 2. J Clin Microbiol. 2012. PMID: 22553244 Free PMC article.
-
Diagnostic value of HPV E6/E7 mRNA in screening for cervical intraepithelial neoplasia grade 2 or worse: A systematic review and meta‑analysis.Oncol Lett. 2024 Mar 26;27(5):231. doi: 10.3892/ol.2024.14364. eCollection 2024 May. Oncol Lett. 2024. PMID: 38586199 Free PMC article.
-
Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis.J Oncol. 2019 Jun 11;2019:6935030. doi: 10.1155/2019/6935030. eCollection 2019. J Oncol. 2019. PMID: 31281360 Free PMC article. Review.
Cited by
-
Evaluation of HPV 16 and HPV 18 Oncoprotein Expression as Alternative Diagnostic Tools in Cervical Lesion.Asian Pac J Cancer Prev. 2024 Feb 1;25(2):521-527. doi: 10.31557/APJCP.2024.25.2.521. Asian Pac J Cancer Prev. 2024. PMID: 38415538 Free PMC article.
-
Multiple infections containing the top five prevalent HPV genotypes and their impact on cervical lesions in Changzhou, China.Hum Vaccin Immunother. 2023 Aug 1;19(2):2245723. doi: 10.1080/21645515.2023.2245723. Hum Vaccin Immunother. 2023. PMID: 37584193 Free PMC article.
-
Prevalence of genotype-specific human papillomavirus in cytology specimens and cervical biopsies, and its implication in cervical cancer risk stratification: a retrospective study of 10647 cases.J Cancer. 2021 Oct 21;12(23):7167-7176. doi: 10.7150/jca.60601. eCollection 2021. J Cancer. 2021. PMID: 34729118 Free PMC article.
-
A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities.Front Public Health. 2021 Jul 1;9:670032. doi: 10.3389/fpubh.2021.670032. eCollection 2021. Front Public Health. 2021. PMID: 34277540 Free PMC article.
-
Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review.Infect Agent Cancer. 2020 Nov 16;15(1):68. doi: 10.1186/s13027-020-00335-2. Infect Agent Cancer. 2020. PMID: 33292364 Free PMC article. Review.
References
-
- Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 0(0). - PubMed
-
- WHO. Integrated Africa Cancer Factsheet Focusing on Cervical Cancer. 2014 [cited 2018 3Oct]; Available from: http://www.who.int/pmnch/media/events/2014/africa_cancer_factsheet.pdf.
-
- WHO, Human Papil-lomavirus and Related Cancers in World . Summary Report 2010. 2010.
Publication types
LinkOut - more resources
Full Text Sources